Jpmorgan Chase & CO Adma Biologics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Adma Biologics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 205,955 shares of ADMA stock, worth $3.8 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
205,955
Previous 239,588
14.04%
Holding current value
$3.8 Million
Previous $2.68 Million
53.73%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding ADMA
# of Institutions
318Shares Held
184MCall Options Held
917KPut Options Held
91.6K-
Black Rock Inc. New York, NY18.6MShares$344 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.1MShares$334 Million0.01% of portfolio
-
State Street Corp Boston, MA13MShares$240 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA12.6MShares$233 Million0.05% of portfolio
-
Morgan Stanley New York, NY8.6MShares$159 Million0.01% of portfolio
About ADMA BIOLOGICS, INC.
- Ticker ADMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 196,356,992
- Market Cap $3.62B
- Description
- ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primar...